Close

Novartis AG recalls 4 over-the-counter drugs

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Novartis AG said Sunday it is voluntarily recalling some over-the-counter products in the U.S., including its Excedrin headache pills and NoDoz medication, because they may contain broken or stray tablets from other products.

The recall also affects its Bufferin and Gas-X Prevention brands.Novartis has temporarily suspended operations at the Lincoln, Neb., plant where the products were made, the company said in a statement.The move comes after consumer complaints “of chipped and broken pills and inconsistent bottle packaging line clearance practices possibly resulting in mixed tablets,” the company said. The over-the-counter medications were distributed throughout the U.S.

Julie Masow, a spokeswoman for the Basel, Switzerland-based company, said she didn’t immediately have a number for the amount of tablets and gel caps involved in the recall. She said there hadn’t been any reports of overdoses or allergic reactions from the stray material or broken and chipped medication. The Lincoln facility’s products account for less than 2 percent of Novartis Group sales, Novartis said. The drugmaker had sales of $50.6 billion in 2010.

The company said it was recalling all lots of bottles containing Excedrin and NoDoz with expiration dates of Dec. 20, 2014, or earlier, as well as Bufferin and Gas-X Prevention with throw-out dates of Dec. 20, 2013, or earlier.

 

Latest stories

Related stories

Roche Looks to Expand its Drug Production in the US

Roche is planning to expand its drug production in...

How Language Barriers Impact Non-Native English Speakers in Healthcare

Language barriers create significant challenges for non-native English speakers...

FDA Approval of AMVUTTRA for ATTR Amyloidosis

Alnylam Pharmaceuticals, Inc., a global leader in RNAi therapeutics,...

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back